TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27695423
Drug: Resveratrol supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol supplementation (200 mg/day)
Study: 25892271
Drug: Eptifibatide along
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide along with intensified antianginal therapy (group A)
Study: 25892271
Drug: Intensified antianginal
Normalized name: ANTIANGINALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified antianginal therapy alone (group B)
Study: 22867975
Drug: Etanercept (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (12.5 mg) administered via intra-articular injections
Study: 16034446
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 30 mg
Study: 21193172
Drug: Atomoxetine (ATM)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATM) 60 mg
Study: 21193172
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (CIT) 30 mg
Study: 29762709
Drug: Relationship between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relationship between anti-KSHV antibodies and KSHV shedding
Study: 29762709
Drug: Relationship between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relationship between antimalarial antibodies and KSHV shedding
Study: 29328637
Drug: Cream containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream containing olive oil squalene
Study: 29328637
Drug: Squalene-containing cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Squalene-containing cream
Study: 31377226
Drug: AQP5 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQP5 levels in urine (measured in ng/mL)
Study: 31377226
Drug: AQP5 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQP5 levels in the highest tertile (16.0 ng/mL)
Study: 25077918
Drug: Acute administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute administration of 8 mg salbutamol
Study: 25077918
Drug: Two-week administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-week administration of 8 mg salbutamol
Study: 22906006
Drug: VXM01 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: VXM01 (oral DNA vaccine)
Study: 17606778
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 200 mg daily for fifty days
Study: 17606778
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500 mg daily for fifty days
Study: 17606778
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 1500 mg daily for fifty days
Study: 10341162
Drug: D-tagatose (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-tagatose (75 g daily for 8 weeks)
Study: 10341162
Drug: D-tagatose (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-tagatose (75 g single dose)
Study: 10341162
Drug: Sucrose (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (25 g with each meal for 8 weeks)
Study: 10341162
Drug: No sugar
Normalized name: polyamino sugar condensate
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sugar supplements (for Type 2 diabetics for 8 weeks)
Study: 2022861
Drug: Polyantibiotic cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyantibiotic cream applied three times daily from the first day of catheterization until bacteriuria was found.
Study: 2022861
Drug: Routine meatal
Normalized name: URETHRAL MEATAL DILATOR ADULT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine meatal care with cleansing of the meatal surface during daily bathing (Control).
Study: 7078021
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of norethindrone acetate and 50 microgram ethinyl estradiol daily for 21 days with 7 days of placebo treatment in each cycle
Study: 7078021
Drug: One fifth
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One fifth of the hormone dose in form of a continuous daily medication
Study: 7078021
Drug: Previous use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous use of oral contraceptives
Study: 18422480
Drug: Prescription omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription omega-3 fatty acid concentrates (P-OM3)
Study: 16638830
Drug: Daily gauze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily gauze dressing
Study: 10975022
Drug: Lidamidine HCL
Normalized name: lidamidine HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidamidine HCL (4 mg) taken orally t.i.d. with food
Study: 8973430
Drug: Separate injections
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injections of DTP-a, Hib conjugate, and i.p.v.
Study: 6146112
Drug: Camazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camazepam (30 mg)
Study: 29572795
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and carboplatinum (first-line therapy)
Study: 29572795
Drug: Cisplatinum-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatinum-based therapy (including doxorubicin and cyclophosphamide)
Study: 24519843
Drug: Impact of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impact of dialysis on daily life
Study: 20814785
Drug: Propofol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (200 mcg/kg/min)
Study: 20814785
Drug: Propofol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (120 mcg/kg/min) plus remifentanil (0.3 mcg/kg/min)
Study: 24092691
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g/kg)
Study: 16247118
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both (brace and physical therapy)
Study: 12073163
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg L-5-hydroxytryptophan
Study: 7749496
Drug: CV 205‐502
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV 205‐502 (0.15 mg)
Study: 7749496
Drug: Octreotide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (0.1 mg)
Study: 7749496
Drug: CV 205‐502
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV 205‐502 (0.3 mg/day) - chronic test
Study: 7749496
Drug: CV 205‐502
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV 205‐502 (0.6 mg/day) and octreotide (0.6 mg/day) - combined therapy for 3 months
Study: 1483496
Drug: Intravenous famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous famotidine (20 mg)
Study: 3791364
Drug: placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo solution
Study: 31168645
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural steroid injections (ESIs)
Study: 29190751
Drug: Beetroot-based gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot-based gel (BG) 100 g containing 12 mmol nitrate
Study: 29190751
Drug: Nitrate-depleted gel
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-depleted gel (PLA) 100 g
Study: 16717300
Drug: N-acetylcysteine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (150 mg/kg mixed in 250 mL of 5% dextrose infused in 20 min, followed by an infusion of 150 mg/kg in 250 mL of 5% dextrose over 24 h)
Study: 29966458
Drug: DNR 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNR 36 mg/m2
Study: 29966458
Drug: DOX 30
Normalized name: BenzoDox 30 Kit
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DOX 30 mg/m2
Study: 24410834
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy with pitavastatin
Study: 24410834
Drug: Intensive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid-lowering therapy with pitavastatin
Study: 19414572
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg iclaprim/kg
Study: 19414572
Drug: 1.6 mg
Normalized name: menthol 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg iclaprim/kg
Study: 19414572
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g vancomycin
Study: 17456225
Drug: Grass allergen
Normalized name: orchardgrass allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass allergen tablet (GRAZAX)
Study: 17456225
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment (antihistamines and topical steroids)
Study: 15006124
Drug: Prescription by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription by general practitioners for brisk exercise (30 minutes per day, 5 days per week)
Study: 15006124
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prescription and counselling
Study: 11605558
Drug: Semantically similar
Normalized name: Antigonadotropins and similar agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantically similar encoding pairs (e.g., alluring-PRETTY)
Study: 11605558
Drug: Semantically contrasting
Normalized name: CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantically contrasting encoding pairs (e.g., drab-PRETTY)
Study: 11605558
Drug: Semantically unrelated
Normalized name: Latanoprost related compound e
DrugBank: Latanoprost acid (DB19360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantically unrelated encoding pairs (e.g., sore-PRETTY)
Study: 11605558
Drug: Semantically similar
Normalized name: Antigonadotropins and similar agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantically similar generation pairs (e.g., beautiful-PRETTY)
Study: 11605558
Drug: Semantically contrasting
Normalized name: CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantically contrasting generation pairs (e.g., ugly-PRETTY)
Study: 9520826
Drug: Demeclocycline (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demeclocycline (1200 mg daily, starting 5 days preoperatively to postoperative day 2)
Study: 8084686
Drug: Training in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training in sports (field hockey and athletics) for 10 weeks, 45 minutes daily
Study: 28688677
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied with an InGaAlP diode (660nm‐100mW‐1J‐4J/cm2)
Study: 9429740
Drug: Direct administration
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct administration into the duodenum (40 mg)
Study: 9429740
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration (40 mg)
Study: 24794721
Drug: Subcutaneous peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous peginterferon beta‐1a 125 μg every 2 weeks
Study: 24794721
Drug: Subcutaneous peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous peginterferon beta‐1a 125 μg every 4 weeks
Study: 20484128
Drug: Letrozole (aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (aromatase inhibitor) to lower estradiol and increase testosterone (group T)
Study: 20484128
Drug: Letrozole plus
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole plus E(2) patches to lower testosterone and raise estradiol (group E)
Study: 12027070
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg albuterol/HFA 134a
Study: 12027070
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg albuterol/HFA 134a
Study: 12027070
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg albuterol/HFA 134a
Study: 12027070
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg albuterol/CFC
Study: 12027070
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg albuterol/CFC
Study: 6682667
Drug: Maalox 70
Normalized name: Maalox
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox 70 (4 x 10 ml/die)
Study: 26011779
Drug: Armodafinil (150‐250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (150‐250 mg/day)
Study: 23230975
Drug: everolimus <3
Approvals — FDA: no, EMA: no, PMDA: no
Description: everolimus <3 ng/mL
Study: 23230975
Drug: everolimus ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: everolimus ≥ 12 ng/mL
Study: 23230975
Drug: everolimus 3-8
Normalized name: everolimus 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: everolimus 3-8 ng/mL and CsA <100 ng/mL
Study: 22105589
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of modafinil (3 doses, given 8 hourly)
Study: 22105589
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of modafinil (3 doses, given 8 hourly)
Study: 22105589
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of modafinil (2 doses) plus placebo (1 dose, given 8 hourly)
Study: 22105589
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 doses, given 8 hourly)
Study: 19761889
Drug: Mashed potato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mashed potato with HV‐HPMC (all doses)
Study: 19761889
Drug: HV‐HPMC doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: HV‐HPMC doses
Study: 11834140
Drug: Glycyrrhetinic acid
Normalized name: Glycyrrhetinic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhetinic acid (GA) 500 mg
Study: 20576419
Drug: Mannitol 240
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol 240 mg
Study: 20576419
Drug: Mannitol 480
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol 480 mg
Study: 17591126
Drug: Propofol administration
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administration with bispectral index monitoring (group B)
Study: 12453546
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral morphine four times daily for 4 days (2.5 mg if creatinine > 200 micromol/l)
Study: 7793547
Drug: Diamorphine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine at highest dose (533 micrograms.h‐1)
Study: 1822492
Drug: Intracervical dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical dinoprostone 0.5 mg gel (Group 1, n = 24)
Study: 1822492
Drug: Intracervical administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracervical administration of PGE2 1.5 mg on Surgicel (Group 2, n = 26)
Study: 1822492
Drug: Intracervical dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical dinoprostone 0.5 mg gel (Group 3, n = 28)
Study: 1822492
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of PGE2 2.25 mg on a Spongel (Group 4, n = 22)
Study: 31498469
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (TTh) injections (>12 injections)
Study: 31498469
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (TTh) topical gels (>330 days supply)
Study: 31498469
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (injection and gel) in nondiabetics
Study: 31498469
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy injections in diabetics
Study: 29800370
Drug: Live-attenuated tetravalent
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-attenuated tetravalent dengue vaccine (TDV)
Study: 27790333
Drug: Lactocare® (Synbiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactocare® (Synbiotic containing 1 billion CFU/Capsule of various probiotics)
Study: 19556719
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin + 300 mg rebamipide
Study: 19556719
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin + placebo
Study: 17886708
Drug: Alternant chemotherapy
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternant chemotherapy
Study: 17886708
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with hematologic support
Study: 17886708
Drug: New targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: New targeted therapy agents or immunotherapeutic approaches
Study: 15793155
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline at 200 mg every 24 h
Study: 2194047
Drug: Progesterone 400
Normalized name: progesterone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone 400 mg
Study: 2194047
Drug: Progesterone 800
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone 800 mg
Study: 369623
Drug: L-5-hydroxytryptophan (L-5HTP)
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-hydroxytryptophan (L-5HTP) with carbidopa
Study: 25265255
Drug: Tacrolimus once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus once-daily formulation (Tac-OD)
Study: 25265255
Drug: Tacrolimus twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus twice-daily formulation (Tac-TD)
Study: 21366473
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (targeting a glycated hemoglobin level below 6.0%)
Study: 21366473
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (targeting a glycated hemoglobin level of 7 to 7.9%)
Study: 18298579
Drug: Didanosine enteric-coated
Normalized name: didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine enteric-coated capsules (ddI-EC) administered in a fasted state (group 1)
Study: 18298579
Drug: Didanosine enteric-coated
Normalized name: didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine enteric-coated capsules (ddI-EC) administered with food (group 2)
Study: 10918483
Drug: DNA/liposome formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA/liposome formulation (plasmid DNA expressing CFTR cDNA complexed with DC‐Chol/DOPE cationic liposomes)
Study: 9005590
Drug: Mepartricin 150,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepartricin 150,000 U (40 mg) administered once-a-day in the evening for 60 days
Study: 1419290
Drug: 3M (mitozantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3M (mitozantrone 6.5 mg/m2 q 21 days, methotrexate 30 mg/m2 q 21 days, mitomycin C 6.5 mg/m2 q 42 days)
Study: 31370792
Drug: Multi-component intervention
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component intervention A (advanced) including nutritional counseling, physical activity, cognitive training, optimization of medication, management of vascular risk factors, social activity, and specific interventions targeting grief and depression
Study: 31370792
Drug: General health
Normalized name: Walgreens Men-General Health Multivitamin Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: General health advice and GP treatment as usual (Intervention B)
Study: 21482863
Drug: Becaplermin gel
Normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Becaplermin gel (0.1% in hydrogel), applied once daily for 8 weeks
Study: 21482863
Drug: Hydrogel dressing,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel dressing, applied once daily for 8 weeks
Study: 21482863
Drug: Becaplermin gel
Normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Becaplermin gel and Hydrogel dressing
Study: 19917839
Drug: Trastuzumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (6 mg/kg every 3 weeks for 1 year)
Study: 12644426
Drug: Continuous i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v. diltiazem 1 micro g kg(‐1) min(‐1)
Study: 10709897
Drug: Fluid regime
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid regime A (60 ml/kg on day 1, increasing to 150 ml/kg over the first week)
Study: 7529606
Drug: G‐CSF and
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF and GM‐CSF
Study: 3395027
Drug: Cefamandole 1-gram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole 1-gram preoperative dose followed by 4 additional postoperative doses at 6-hour intervals
Study: 3395027
Drug: Cefamandole 2-gram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole 2-gram doses
Study: 3395027
Drug: Cefoxitin 2-gram
Normalized name: cefoxitin
DrugBank: Cefoxitin (DB01331)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefoxitin 2-gram doses
Study: 30016417
Drug: Passive air-suspension
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive air-suspension seat (control)